US › Healthcare

BioLineRx Ltd (BLRX)

US · Healthcare · Biotechnology

$2.76+3.88%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$477,000

Revenue YoY

+87.1%

Net profit

$-2.6M

Profit YoY

-150.3%

EPS

$-0.58

EPS estimate

$-1.04

Net margin

-541.1%

EPS came in at -0.58 against a street estimate of -1.04 — a beat of 44.0%.

Key statistics

Market cap

$12.0M

P/E

0.0

Forward P/E

93.5

P/B

0.73

Book value

$3.60

EPS (TTM)

$0.00

52-week high

$4.56

52-week low

$2.15

50-day MA

$3.12

200-day MA

$3.00

Beta

0.71

Analyst view

Analysts rate BioLineRx Ltd a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $17.50.

Shareholding

Insiders

3.91%

Institutions

0.45%

Largest institutional holders

Fund	Stake
XTX Topco Ltd	0.25%
Rhumbline Advisers	0.05%
BNP Paribas Arbitrage, SA	0.04%
Wells Fargo & Co	0.04%
Citigroup Inc	0.04%
UBS Group AG	0.01%
Goss Wealth Management LLC	0.00%
Morgan Stanley - Brokerage Accounts	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for BioLineRx Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.